nonsteroidal antiandrogen

This page covers all nonsteroidal antiandrogen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting androgen receptor, Androgen receptor, Androgen receptor; GnRH receptor (depending on specific agents used).

Targets

androgen receptor · Androgen receptor · Androgen receptor; GnRH receptor (depending on specific agents used)

Phase 3 pipeline (4)

• Placebo of Darolutamide · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie · Oncology
  Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues.
• Long-term course of antiandrogen drugs · The First Affiliated Hospital with Nanjing Medical University · Oncology
  Antiandrogen drugs block the effects of androgens (male hormones) by inhibiting androgen receptor signaling.
• Adjuvant Androgen-Deprivation Therapy · National Taiwan University Hospital · Oncology
  Adjuvant androgen-deprivation therapy suppresses testosterone production to inhibit the growth of hormone-sensitive prostate cancer cells after primary treatment.
• Standard Darolutamide · Jena University Hospital · Oncology
  Darolutamide is a nonsteroidal antiandrogen that competitively inhibits the action of androgens, such as testosterone and dihydrotestosterone, at their receptor sites in various tissues.

Phase 2 pipeline (1)

• Bicalutamide Oral Product · Gynaecologisch Oncologisch Centrum Zuid · Oncology
  Bicalutamide is a nonsteroidal antiandrogen that inhibits the action of androgens.

Patent intelligence

• antiandrogen patent landscape — aggregated cliff calendar, attackable patents, originator estates